CompletedNCT02255513
Safety study of HLD200 in ADHD
Researchers compared HLD200 and placebo, tracking side effects to assess safety in children with ADHD.
Medication studyAges 6–12United States
Understand this study
What did researchers investigate?
Researchers compared HLD200 and placebo, tracking side effects to assess safety in children with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
- Listed locations
- Newport Beach and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 43
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT02255513
- Official title
Show the full official title
A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.
Get this study by email
Recruitment & locations
CompletedNewport Beach · Marshfield · Las Vegas
1 more locations
- Durham
Questions about this study
What did researchers investigate?
Researchers compared HLD200 and placebo, tracking side effects to assess safety in children with ADHD.
Who is behind this study?
The study sponsor is Ironshore Pharmaceuticals and Development, Inc.
Did this study involve medication?
Yes. The study involved medication, including HLD200 and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 12 years. Other eligibility criteria applied.
